Literature DB >> 24699988

Clinical radiobiology of glioblastoma multiforme: estimation of tumor control probability from various radiotherapy fractionation schemes.

Piernicola Pedicini1, Alba Fiorentino, Vittorio Simeon, Paolo Tini, Costanza Chiumento, Luigi Pirtoli, Marco Salvatore, Giovanni Storto.   

Abstract

BACKGROUND AND
PURPOSE: The aim of this study was to estimate a radiobiological set of parameters from the available clinical data on glioblastoma (GB). PATIENTS AND METHODS: A number of clinical trial outcomes from patients affected by GB and treated with surgery and adjuvant radiochemotherapy were analyzed to estimate a set of radiobiological parameters for a tumor control probability (TCP) model. The analytical/graphical method employed to fit the clinical data allowed us to estimate the intrinsic tumor radiosensitivity (α), repair capability (b), and repopulation doubling time (T d ) in a first phase, and subsequently the number of clonogens (N) and kick-off time for accelerated proliferation (T(k)). The results were used to formulate a hypothesis for a schedule expected to significantly improve local control. The 95 % confidence intervals (CI(95 %)) of all parameters are also discussed.
RESULTS: The pooled analysis employed to estimate the parameters summarizes the data of 559 patients, while the studies selected to verify the results summarize data of 104 patients. The best estimates and the CI(95 %) are α = 0.12 Gy⁻¹ (0.10-0.14), b = 0.015 Gy⁻² (0.013-0.020), α/b = 8 Gy (5.0-10.8), T(d)  = 15.4 days (13.2-19.5), N = 1.10⁴(1.2.10³ - 1.10⁵), and T(k)  = 37 days (29-46). The dose required to offset the repopulation occurring after 1 day (D(prolif)) and starting after T k was estimated as 0.30 Gy/day (0.22-0.39).
CONCLUSION: The analysis confirms a high value for the α/b ratio. Moreover, a high intrinsic radiosensitivity together with a long kick-off time for accelerated repopulation and moderate repopulation kinetics were found. The results indicate a substantial independence of the duration of the overall treatment and an improvement in the treatment effectiveness by increasing the total dose without increasing the dose fraction.

Entities:  

Mesh:

Year:  2014        PMID: 24699988     DOI: 10.1007/s00066-014-0638-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  29 in total

1.  In regard to Pedicini et al.

Authors:  Piernicola Pedicini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-12-01       Impact factor: 7.038

2.  Can MGMT promoter methylation status be used as a prognostic and predictive marker for glioblastoma multiforme at the present time? A word of caution.

Authors:  R Fietkau; F Putz; G Lahmer; S Semrau; R Buslei
Journal:  Strahlenther Onkol       Date:  2013-11-02       Impact factor: 3.621

3.  Estimation of a self-consistent set of radiobiological parameters from hypofractionated versus standard radiation therapy of prostate cancer.

Authors:  Piernicola Pedicini; Lidia Strigari; Marcello Benassi
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-01-17       Impact factor: 7.038

4.  Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.

Authors:  Mario Balducci; Giuseppina Apicella; Stefania Manfrida; Annunziato Mangiola; Alba Fiorentino; Luigi Azario; Giuseppe Roberto D'Agostino; Vincenzo Frascino; Nicola Dinapoli; Giovanna Mantini; Alessio Albanese; Pasquale de Bonis; Silvia Chiesa; Vincenzo Valentini; Carmelo Anile; Numa Cellini
Journal:  Strahlenther Onkol       Date:  2010-09-30       Impact factor: 3.621

5.  Low-dose fractionated radiotherapy and concomitant chemotherapy in glioblastoma multiforme with poor prognosis: a feasibility study.

Authors:  Mario Balducci; Silvia Chiesa; Barbara Diletto; Giuseppe Roberto D'Agostino; Annunziato Mangiola; Stefania Manfrida; Giovanna Mantini; Alessio Albanese; Alba Fiorentino; Vincenzo Frascino; Berardino De Bari; Francesco Micciche'; Fiorenza De Rose; Alessio Giuseppe Morganti; Carmelo Anile; Vincenzo Valentini
Journal:  Neuro Oncol       Date:  2011-10-12       Impact factor: 12.300

6.  Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study.

Authors:  S W Lee; B A Fraass; L H Marsh; K Herbort; S S Gebarski; M K Martel; E H Radany; A S Lichter; H M Sandler
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-01-01       Impact factor: 7.038

7.  A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.

Authors:  Alessio G Morganti; Mario Balducci; Maurizio Salvati; Vincenzo Esposito; Pantaleo Romanelli; Marica Ferro; Franco Calista; Cinzia Digesù; Gabriella Macchia; Massimo Ianiri; Francesco Deodato; Savino Cilla; Angelo Piermattei; Vincenzo Valentini; Numa Cellini; Gian Paolo Cantore
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-14       Impact factor: 7.038

8.  Estimate of the accelerated proliferation by protein tyrosine phosphatase (PTEN) over expression in postoperative radiotherapy of head and neck squamous cell carcinoma.

Authors:  P Pedicini; A Fiorentino; G Improta; A Nappi; M Salvatore; G Storto
Journal:  Clin Transl Oncol       Date:  2013-03-05       Impact factor: 3.405

9.  A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity.

Authors:  S A Roberts; J H Hendry
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-06-01       Impact factor: 7.038

10.  Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.

Authors:  Valerie Panet-Raymond; Luis Souhami; David Roberge; Petr Kavan; Lily Shakibnia; Thierry Muanza; Christine Lambert; Richard Leblanc; Rolando Del Maestro; Marie-Christine Guiot; George Shenouda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-06-12       Impact factor: 7.038

View more
  19 in total

Review 1.  Clinical implications of in silico mathematical modeling for glioblastoma: a critical review.

Authors:  Maria Protopapa; Anna Zygogianni; Georgios S Stamatakos; Christos Antypas; Christina Armpilia; Nikolaos K Uzunoglu; Vassilis Kouloulias
Journal:  J Neurooncol       Date:  2017-10-28       Impact factor: 4.130

2.  Temozolomide during radiotherapy of glioblastoma multiforme : Daily administration improves survival.

Authors:  Silke Birgit Nachbichler; Gabi Schupp; Hendrik Ballhausen; Maximilian Niyazi; Claus Belka
Journal:  Strahlenther Onkol       Date:  2017-02-14       Impact factor: 3.621

3.  Clinical radiobiology of head and neck cancer: the hypothesis of stem cell activation.

Authors:  P Pedicini; R Caivano; A Fiorentino; L Strigari
Journal:  Clin Transl Oncol       Date:  2014-12-09       Impact factor: 3.405

4.  MRI during radiotherapy of glioblastoma : Does MRI allow for prognostic stratification?

Authors:  C Leitzen; T Wilhelm-Buchstab; L C Schmeel; S Garbe; S Greschus; T Müdder; S Oberste-Beulmann; B Simon; H H Schild; H Schüller
Journal:  Strahlenther Onkol       Date:  2016-06-03       Impact factor: 3.621

5.  CT-guided interstitial HDR-brachytherapy for recurrent glioblastoma multiforme: a 20-year single-institute experience.

Authors:  Georgios Chatzikonstantinou; Nikolaos Zamboglou; Eleftherios Archavlis; Iosif Strouthos; Eleni Zoga; Natasha Milickovic; Basil Hilaris; Dimos Baltas; Claus Rödel; Nikolaos Tselis
Journal:  Strahlenther Onkol       Date:  2018-09-10       Impact factor: 3.621

6.  Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme.

Authors:  Annekatrin Seidlitz; Timo Siepmann; Steffen Löck; Tareq Juratli; Michael Baumann; Mechthild Krause
Journal:  Radiat Oncol       Date:  2015-08-16       Impact factor: 3.481

7.  Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.

Authors:  Melissa Azoulay; Fabiano Santos; Luis Souhami; Valerie Panet-Raymond; Kevin Petrecca; Scott Owen; Marie-Christine Guiot; Mariia Patyka; Siham Sabri; George Shenouda; Bassam Abdulkarim
Journal:  Radiat Oncol       Date:  2015-04-26       Impact factor: 3.481

8.  Fast and high temperature hyperthermia coupled with radiotherapy as a possible new treatment for glioblastoma.

Authors:  Giovanni Borasi; Alan Nahum; Margarethus M Paulides; Gibin Powathil; Giorgio Russo; Laura Fariselli; Debora Lamia; Roberta Cirincione; Giusi Irma Forte; Cristian Borrazzo; Barbara Caccia; Elisabetta di Castro; Silvia Pozzi; Maria Carla Gilardi
Journal:  J Ther Ultrasound       Date:  2016-12-08

9.  Survival impact of prolonged postoperative radiation therapy for patients with glioblastoma treated with combined-modality therapy.

Authors:  Mehran B Yusuf; Jeremy Gaskins; Mark J Amsbaugh; Shiao Woo; Eric Burton
Journal:  Neurooncol Pract       Date:  2018-07-20

10.  Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy.

Authors:  Paolo Tini; Valerio Nardone; Pierpaolo Pastina; Giuseppe Battaglia; Clelia Miracco; Lucio Sebaste; Giovanni Rubino; Alfonso Cerase; Luigi Pirtoli
Journal:  Biomed Res Int       Date:  2017-10-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.